This inventor holds 3 USPTO granted patents, plus 2 CIPO patents and 5 EPO patents. Top assignee: Glaxosmithkline Intellectual Property Development Limited. Active years: 2017-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017-2019
Title: Michael P. Demartino: Innovator in Pharmaceutical Compounds
Introduction
Michael P. Demartino is a notable inventor based in King of Prussia, Pennsylvania. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific kinases involved in various diseases. With a total of three patents to his name, his work has the potential to impact therapeutic approaches for numerous gastrointestinal and cancer-related disorders.
Latest Patents
One of Michael P. Demartino's latest patents focuses on novel compounds that act as inhibitors of the Rearranged during Transfection (RET) kinase. This invention encompasses pharmaceutical compositions containing these compounds, as well as processes for their preparation. The therapeutic applications of these compounds are extensive, targeting conditions such as irritable bowel syndrome (IBS), functional gastrointestinal disorders, and various types of cancer, including non-small cell lung cancer and colorectal cancer. The potential benefits of these compounds extend to the normalization of gastrointestinal sensitivity, motility, and secretion, making them a promising avenue for treatment.
Career Highlights
Michael P. Demartino is currently associated with GlaxoSmithKline Intellectual Property Development Limited, where he continues to innovate in the pharmaceutical sector. His work is characterized by a strong focus on developing therapeutic solutions that address complex medical conditions. His expertise in the field has positioned him as a valuable contributor to advancements in drug development.
Collaborations
Throughout his career, Michael has collaborated with talented individuals such as Mui Cheung and Hilary Schenck Eidam. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to the development of impactful pharmaceutical solutions.
Conclusion
Michael P. Demartino's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to improving therapeutic options for patients. His work in developing RET inhibitors showcases the potential for significant advancements in treating gastrointestinal and cancer-related disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile